Table I.
Subject Disposition and Demographic Characteristics
| Placebo | TQ 300 mg | TQ 600 mg | TQ 1200 mg | Moxifloxacin | |
|---|---|---|---|---|---|
| Randomized | 52 | 52 | 52 | 52 | 52 |
| Completed study | 50 | 48 | 52 | 50 | 51 |
| Withdrawn | 2 | 4 | 0 | 2 | 1 |
| Safety population | 52 | 52 | 52 | 52 | 52 |
| ECG evaluable | 50 | 48 | 52 | 50 | 51 |
| PK evaluable | 0 | 51 | 52 | 51 | 52 |
| PK/PD evaluable | 52 | 51 | 52 | 51 | 52 |
| Sex, male | 32 | 38 | 36 | 36 | 39 |
| Ethnicity | |||||
| Caucasian | 29 | 28 | 26 | 31 | 28 |
| African/African American | 19 | 21 | 23 | 21 | 19 |
| Othera | 4 | 3 | 3 | 0 | 5 |
| Mean age (year) (SD) | 34.4 (10.6) | 35.0 (10.9) | 38.7 (11.8) | 36.0 (10.1) | 34.4 (9.8) |
All values are number in each category except for age. TQ, tafenoquine.
a
American Indian/Alaskan Native (3), Asian (6), Native Hawaiian or other pacific islander (2), African-American and White (3), or Asian and White (1).